Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China

Jie Zha1,2†, Liyuan Fan1,2†, Shuhua Yi3†, Haifeng Yu4,5†, Zhong Zheng6†, Wei Xu7†, Manman Deng1,2†, Zhijuan Lin1,2, Zhifeng Li1,2, Lingyan Ping8, Xiaohua He9,10,11, Feili Chen12, Ying Xie13, Biyun Chen13, Huihai Zhang14, Li Wang7, Kaiyang Ding15, Wenyu Li12, Haiyan Yang4,5, Weili Zhao6, Lugui Qiu3, Zhiming Li9,10,11*, Yuqin Song8* and Bing Xu1,2*

Abstract
Clinical features and outcomes of FL patients in Chinese population are limited, thus promoting us to perform this analysis on a large cohort of 1845 patients with FL enrolled from nine medical centers nationwide in China. In this cohort, the median age of patients at diagnosis was 53 years, which was comparable to that reported previously for Chinese FL patients (49–51 years) but younger than that for Western FL patients (60–65 years). In contrast with Western patients, Chinese FL patients more likely involved extranodal sites but less frequently infiltrated bone marrow. Other clinical characteristics were comparable between two populations. In this study, 91% of patients were managed with chemotherapy, yielding 72% and 46% of overall-response rate and complete remission. After median 55-month follow-up, 5-year progressive-free and overall survival were 61% and 89%, respectively. Both were analogous to those reported in prior Chinese and Western studies. Consistent with published data, addition of rituximab into both induction (Ri) and maintenance (Rm) treatment led to the most favorable outcomes. Interestingly, Ri only had better outcomes than Rm only. Notably, 7% of patients experienced histologic transformation (HT) and correlated with poor survival. Of the transformed FL cases, 3% and 4% of HT events occurred prior to or post-treatment, respectively. Importantly, the latter displayed worse outcomes than the former. Altogether, this study provides real-world information of the largest cohort of FL patients so far in China, which might lay a foundation for clinical investigation of Chinese FL in future.

Keywords: Follicular lymphoma (FL), Chinese, Rituximab, Chemotherapy, Histological transformation (HT)

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

To the editor,

Follicular lymphoma (FL), a common indolent B-cell lymphoma, is characterized by its high heterogeneity in clinical characteristics and outcomes [1]. Demographics, clinical characteristics, treatment patterns and outcomes of FL patients have been well documented in Western countries [2, 3]. However, this information is largely lacking in China. To understand clinical presentations, treatments and prognosis of Chinese FL patients, we performed a retrospective multicenter study, which enrolled 1845 patients (age > 18 years) with newly diagnosed FL
between 2000 and 2020 in China. Patients and methods for this study are described in detail in Additional file 1.

Demographics and clinical characteristics of the patients enrolled in this study are summarized in Table 1. The median age at diagnosis was 53 years in our cohort, similar to that reported earlier for Chinese FL patients (49–51 years) but much younger than that reported in Western cohorts (60–65 years) [2–5]. Consistent with the prior study from China [4], Chinese FL patients had relatively lower rate of ECOG ≤ 1 than non-Chinese counterparts, reflecting poor performance status; moreover, approximately 40% of Chinese FL patients had extranodal involvement sites of >1, significantly higher than that demonstrated in the cohorts of Western countries (5–25%) [2, 3]. Although the incidence of bone-marrow infiltration (BMI) in this cohort (28%) was higher than that reported previously for Chinese FL patients (15.2%) [4], the BMI rates in Chinese FL patients were lower than that in Western patients (29–52%) [2–4]. Other clinical features of FL patients in our cohort were comparable to those reported for Chinese FL patients and in the Western cohorts [2–5].

Treatment patterns and therapeutic responses are detailed in Additional file 2. In our cohort, 91% of FL patients received systemic chemotherapies, among which CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) ± rituximab (R) was the most frequently used regimen, probably representing the major regimen for frontline treatment of FL in China, in accordance with the earlier report [4]. However, only 1% of patients received bendamustine plus rituximab, due to unavailability of bendamustine in China until 2019 [6]. Unlike approximately 20% of FL patients treated with observation in the cohorts of Western countries [7], only 7% of Chinese FL patients were administered with watchful waiting. In the study, overall response rate (ORR) was 72% with 46% complete remission (CR). 5-year progression-free (PFS) and overall survival (OS) for all patients were 61% and 89%, respectively (Fig. 1A, B). Both were analogous to those observed previously in Chinese FL patients and several Western cohorts [4, 8, 9]. We found that rituximab-based induction therapy (Ri) followed by rituximab maintenance (Rm) resulted in the best outcomes (both PFS and OS), consistent with the findings from another real-world study in Chinese population [10]. R, only was superior to Rm only (Fig. 1C, D). This observation suggests that incorporating rituximab into induction treatment might be more beneficial than using rituximab for maintenance if patients could not afford long-term usage of this costly agent.

Histological transformation (HT) represents a crucial feature of FL and correlates with unfavorable outcomes [11]. Transformed FL (t-FL) can happen prior to or post-chemotherapy [12]. In our cohort, 125 patients (7%) experienced HT, of which 3% and 4% of transformed cases were observed prior to or post-treatment, respectively. Analogous to those described in previous studies involving Western countries, patients with t-FL displayed poorer outcomes than those with non-transformed FL (nt-FL; Fig. 1E; P = 0.0002). In this study, patients with t-FL prior to treatment had 87% of 5-year OS, which was similar to those with nt-FL but significantly better than

### Table 1 Baseline patient and disease characteristics in the entire cohort (n = 1845)

| Characteristics                        | N (%)   |
|----------------------------------------|---------|
| Age (median, range)                    | 53 (18–95) |
| Gender                                 |         |
| Female                                 | 976 (53%) |
| Male                                   | 869 (47%) |
| ECOG                                    |         |
| 0–1                                    | 1569 (85%) |
| 2–4                                    | 105 (6%)  |
| Histological grade                     |         |
| 1–2                                    | 1093 (59%) |
| 3                                      | 644 (35%)  |
| Disease stage                          |         |
| I/II                                   | 364 (20%) |
| III/IV                                 | 1365 (74%) |
| B symptoms                             |         |
| No                                     | 792 (43%) |
| Yes                                    | 257 (13%)  |
| Lymph node > 4                         |         |
| No                                     | 721 (39%) |
| Yes                                    | 996 (54%)  |
| > 1 EN site                            |         |
| No                                     | 733 (40%) |
| Yes                                    | 779 (42%)  |
| Bulky disease                          |         |
| No                                     | 1247 (68%) |
| Yes                                    | 385 (21%)  |
| Marrow involved                        |         |
| No                                     | 1263 (68%) |
| Yes                                    | 521 (28%)  |
| HGB < 120 g/l                          |         |
| No                                     | 1343 (73%) |
| Yes                                    | 423 (23%)  |
| LDH > 1 ULN                            |         |
| No                                     | 1251 (68%) |
| Yes                                    | 481 (26%)  |
| β2-MG > 3                              |         |
| No                                     | 977 (53%) |
| Yes                                    | 868 (47%)  |
those whose disease was transformed post-chemotherapy (Fig. 1F; \( P = 0.040 \)). This observation suggests that patients with t-FL prior to therapy could be treated as those with nt-FL, but intensive chemotherapies should be administered for patients with t-FL post-therapy.

This study reveals that Chinese FL patients were much younger and had higher extranodal involvement but lower BM infiltration than Western FL patients. Most Chinese FL patients received systemic chemotherapies, with CHOP \( \pm \) R representing the most common regimen. In terms of ORR, CR, PFS and OS of FL patients, no significant difference was observed between our cohort and the cohorts previously reported in China and Western countries. \( R_i \) plus \( R_m \) yielded the most favorable outcome, while \( R_i \) only was superior to \( R_m \) only when they were applied separately. 7\% of FL patients underwent HT, of which 3\% and 4\% of cases transformed prior to or post-chemotherapy. The latter had poorer outcome than the former. Collectively, this large retrospective study outlines the clinical features and outcomes of Chinese FL patients, which might lay a foundation for future clinical investigation of FL in China.

**Abbreviations**

FL: Follicular lymphoma; ORR: Overall response rate; CR: Complete remission; HT: Histologic transformation; PFS: Progressive-free survival; OS: Overall survival; t-FL: Transformed follicular lymphoma; CHOP: Cyclophosphamide, doxorubicin, vincristine and prednisone; BR: Bendamustine plus rituximab; \( R_i \): Rituximab-based induction therapy; \( R_m \): Rituximab maintenance; nt-FL: Non-transformed FL.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13045-021-01139-6.

**Additional file 1:** Patients and methods.
**Additional file 2:** Table S1. Treatment pattern and clinical response overview based on distinct therapeutic approaches.

**Acknowledgements**

We thank all physicians, nurses, and particularly patients involved in this study at nine medical centers. Especially, we also thank Prof. Tongyu Lin (Sichuan Cancer Hospital) for his kind supervision and support in designing and conducting this study. In addition, we deeply appreciate the Chinese Workshop on Follicular Lymphoma to provide pivotal suggestions and support this work.

**Authors’ contributions**

JZ, LYF, ZML, YQS, BX took part in conception and design. JZ, LYF, SHY, HFY, ZZ involved in research performance. JZ, LYF, SHY, HFY, ZZ, WX, MMD, ZJL, ZFL, LYP, XHH, FLC, YX, BYC, HLZ, LW, KYD, WYL, HYY, WLZ, LGQ, ZML, YQS, BX took part in collection and assembly of clinical data. JZ, LYF, SHY, ZZ, WX, MMD, ZJL, ZFL participated in data analysis and interpretation. ZJ, MMD and BX involved in manuscript writing. ZJ, ZML, YQS, BX participated in study supervision. All authors read and approved the final manuscript.

**Funding**

This work was financially supported by the National Natural Science Foundation of China (Nos. 81770126, 81770161, 81800163), the Fujian Natural Science Foundation of China (No. 2020J011246), the Xiamen Municipal Bureau of Science and Technology (No. 35022220209003) and the Lymphoma Research Fund of Chinese Anti-Cancer Association (No. CORP-117).
Availability of data and materials
All datasets supporting the conclusions of this study are included in the figures, tables and additional files.

Declarations

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China. 2. Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China. 3. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital and Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. 4. Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. 5. Department of Lymphoma, Institute of Cancer and Basic Medicine (iBMC), Chinese Academy of Sciences, Hangzhou, China. 6. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. 7. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. 8. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China. 9. Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. 10. State Key Laboratory of Oncology in South China, Guangzhou, China. 11. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 12. Lymphoma Division, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 13. Shengli Clinical Medical College of Fujian Medical University, Department of Hematology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China. 14. Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin, China. 15. Department of Hematology, The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, China.

Received: 30 May 2021   Accepted: 10 August 2021
Published online: 23 August 2021

References
1. Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316–27.
2. Federico M, Vitolo U, Zinzani PL, Chiesi T, Clò V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergroupo Italiano Linfomi. Blood. 2000;95(3):783–9.
3. Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol. 2015;170(1):85–95.
4. Zhou Y, Qin Y, He X, Liu P, Yang J, Zhou L, et al. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: a China single-center retrospective study. Asia Pac J Clin Oncol. 2021;17(3):289–99.
5. Song Y, Zhang H, Yang H, Liu A, Cen X, Zhu J, Wen Y, et al. Baseline characteristics of 3046 non-Hodgkin’s lymphoma patients diagnosed between July 2015 and May 2018: a report from China Lymphoma Patient Registry (CLAP). Blood. 2018;132(Supplement 1):S394.
6. Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020;136(23):2626–37.
7. Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, et al. Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era. Br J Haematol. 2016;172(5):724–34.
8. Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984–91.
9. Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLLUS trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506–13.
10. Huang HH, Wen YC, Chen HM, Hsiao FY, Ko BS. Rituximab maintenance improves overall survival in follicular lymphoma: a retrospective nationwide real-world analysis from Taiwan Cancer Registry Database. Cancer Med. 2018;7(8):3582–91.
11. Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood. 2015;125(1):40–7.
12. Rusconi C, Anastasia A, Chiarenza A, Marcheselli L, Cavallo F, Rattotti S, et al. Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL). Br J Haematol. 2019;185(4):713–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions